Romero Jorge, Avendano Ricardo, Diaz Juan Carlos, Taveras Jose, Lupercio Florentino, Di Biase Luigi
a Department of Cardiology , Montefiore Medical Center, Albert Einstein College of Medicine , Bronx , NY , USA.
Expert Rev Cardiovasc Ther. 2019 Jan;17(1):31-41. doi: 10.1080/14779072.2019.1550718. Epub 2018 Dec 18.
Atrial fibrillation is the most common arrhythmia worldwide. Its increasing prevalence has made the use of oral anticoagulants for stroke prevention routine; however, their use after the blanking period of catheter ablation remains uncertain. Areas covered: This review outlines the pros and cons of stopping oral anticoagulation after catheter ablation. Major databases such as Pubmed or Embase were used. The most relevant articles published were used along with major recommendations of society guidelines. Authors will also discuss different proposed mechanisms of atrial fibrillation and more importantly future directions in this topic. Expert commentary: The use of oral anticoagulants after catheter ablation for atrial fibrillation is debatable; however, based on current guidelines, we support the use of oral anticoagulants after the blanking period of catheter ablation. Noteworthy is that although the risk of bleeding can be fatal in some cases, it does not outweigh the risk of a disabling stroke.
心房颤动是全球最常见的心律失常。其患病率不断上升,使得使用口服抗凝药预防卒中成为常规操作;然而,在导管消融空白期后使用口服抗凝药仍不明确。涵盖领域:本综述概述了导管消融后停用口服抗凝药的利弊。使用了诸如PubMed或Embase等主要数据库。使用了已发表的最相关文章以及社会指南的主要建议。作者还将讨论心房颤动不同的提出机制,更重要的是该主题的未来方向。专家评论:导管消融后使用口服抗凝药存在争议;然而,根据当前指南,我们支持在导管消融空白期后使用口服抗凝药。值得注意的是,尽管出血风险在某些情况下可能是致命的,但它并不超过致残性卒中的风险。